Precision Liquid Suspension – Formulated in PEG-400 for reliable consistency across research applications.
Built-In Measured Dropper – Accurate for dependable measurement in every milliliter.
Third-Party Verified – Independent lab testing ensures authenticity and purity of every batch.
For Research Use Only – Distributed exclusively for laboratory purposes, not intended for human use.
High-Quality Liquid Cardarine for Sale
Cardarine, also known as GW-501516 or Endurobol, is a PPAR (peroxisome proliferator-activated receptor) agonist and ligand-activated transcription factor that binds to receptors in skeletal muscle tissue and body fat and pushes skeletal muscle cells towards preferential lipid utilization and fat burning. PPAR is also involved in inflammation, glucose homeostasis, as well as cell proliferation, differentiation, and apoptosis, suggesting potential anti-aging effects of PPAR agonists.
PPARs are located in the greatest concentration in tissues with high metabolic rates, such as skeletal muscle, intestine, liver, heart, and kidney. GW-501516 is often wrongly classified as a selective androgen receptor modulator (SARM). As a PPAR, it shares certain commonalities with SARMs but differs from them in a few crucial ways. GW-501516 does not affect androgen receptors or alter testosterone levels; however, it plays a key role in energy metabolism.
FAQs
GW-501516 does not interact with the androgen receptor at all, so it does not cause suppression of natural testosterone.
Cardarine is non-hormonal and is not known to interrupt menstrual cycles or cause virilization in female test subjects. Quantities as high as 18 mg per day have been used in clinical trials for females. Pregnant women or women who may become pregnant should not engage in clinical research with Cardarine.
GW-501516 has been shown to increase HDL and decrease LDL in rhesus monkeys.
While Cardarine is often sold and marketed alongside SARMs, it is a PPAR agonist and binds and activates PPAR receptors in the body. These receptors have limited involvement in anabolism and play a role in reducing inflammation and improving energy metabolism.
Why is Sports Technology Labs the best place to buy Cardarine online?
A recent study involving chemical analyses of 44 different products sold and marketed as SARMs on the internet revealed that quality control in this industry varies significantly from one company to the next. Only 52% of the products tested contained the product advertised, 59% contained amounts that differed from the label, a shocking 39% contained other unapproved drugs, 25% contained substances not listed on the label, and 9% contained no active substance at all. It is critical when performing research with SARMs to only purchase the highest quality, verified by third-party analysis.
If you are trying to figure out where to buy Cardarine, which many researchers consider one of the best SARMs for cutting body fat, there appears to be no shortage of options out there. Sports Technology Labs is the best place to buy Cardarine online because of their consistent, verifiable, high-quality products, safe bottling and packaging, fast shipping, and excellent customer service. Our Cardarine is also available in pure powder form.
When you buy SARMs from Sports Technology Labs, you are choosing the highest quality ingredients. Minimum 98% pure compounds tested and certified by accredited American third-party labs, suspended in USP-grade (the highest grade) PEG-400, bottled in America. Our products come in glass bottles with fixed glass droppers to prevent the leaching of unwanted plasticizers like BPA, and to avoid contamination by eliminating the need for external measuring tools.
We run a transparent business, with no discreet payment methods necessary and no misrepresentation of our products, only the highest quality research chemicals available online, secured by our 60-day money-back guarantee. We offer free shipping on orders over $149, and if you need the products in a hurry, we offer express shipping as well. Customers who sign up for our email list get 10% off, and an additional 10% off for payment with cryptocurrency.
At Sports Technology Labs, you can find SARMs for sale, including the highest quality Cardarine available online. That’s why we are confident in our claim that we offer the best GW-501516 for sale on the market today. And if you have any questions about our liquid GW-501516 products, you can also contact us, and we’ll respond as soon as possible.
Additional information
Weight
3.0 oz
Certificate Of Analysis
All Sports Technology Labs SARMs are third-party tested by MZ Biolabs, an independent laboratory based in Arizona. Each batch is bottled and tested in the USA to ensure accuracy and purity. Our Certificates of Analysis confirm that products meet the listed specifications:
Cardarine (GW-501516), also referred to as GW1516, is a synthetic PPARδ (Peroxisome Proliferator-Activated Receptor delta) agonist developed in the early 1990s through pharmaceutical research programs, including those by GlaxoSmithKline. It was originally investigated as a potential treatment for metabolic and cardiovascular diseases, including heart disease, dyslipidemia, and type 2 diabetes. Early animal research and short-term human clinical trials suggested that GW-501516 could enhance fatty acid oxidation, improve energy expenditure, and influence lipid metabolism, making it a subject of ongoing interest in metabolic research.
Unlike selective androgen receptor modulators (SARMs), Cardarine does not act on androgen receptors. Instead, it binds to and activates PPARδ, a nuclear receptor that regulates the transcription of genes involved in fatty acid transport, lipid catabolism, glucose uptake, mitochondrial function, and energy metabolism. Activation of these pathways has been shown in preclinical models to shift skeletal muscle toward greater fatty acid utilization, improve endurance capacity, and stabilize metabolic efficiency. These mechanisms explain why Cardarine has been widely discussed in both scientific literature and athletic performance communities.
However, these findings must be understood in context. Human clinical trials were discontinued after long-term rodent studies found rapid development of cancers in multiple organs, including the liver, stomach, and thyroid, at high experimental doses. Additional studies raised concerns about liver toxicity, blood lipid alterations, and other health risks associated with prolonged exposure. Because of these safety concerns, the World Anti-Doping Agency (WADA) has banned GW-501516, and several endurance athletes have tested positive for Cardarine, resulting in strict anti-doping sanctions. Regulatory agencies, including the U.S. FDA, have not approved Cardarine for human use. It is not a dietary supplement and is not legally marketed as one in the United States.
Despite these warnings, Cardarine is sometimes misrepresented online as a weight-loss or endurance aid. Some retailers sell GW-501516 in powder form or as a liquid research chemical, promoting claims related to fat burning, weight loss, and workout performance. These claims are based largely on preclinical animal studies and short-term trials, and do not constitute medical advice or evidence of safety. Reported adverse effects include stomach pain, liver toxicity, and carcinogenicity in animal studies, making the risks far outweigh any unproven benefits.
In summary, Cardarine GW-501516 is a research compound that acts as a potent PPARδ agonist, influencing genes involved in energy metabolism and fatty acid oxidation. While it remains of interest for experimental models studying lipid metabolism, endurance physiology, and insulin sensitivity, its use in humans is associated with serious health risks. GW-501516 is not FDA-approved, not a supplement, and is intended strictly for laboratory research. All research involving this compound should follow applicable regulations, controlled dosing protocols, and institutional safety guidelines to minimize risk and maintain research integrity.
Mechanism of Action
Cardarine (GW-501516, also referred to as GW1516) is a small-molecule PPARδ (Peroxisome Proliferator-Activated Receptor delta) agonist developed in the early 1990s through pharmaceutical research programs. It exhibits low-nanomolar potency for PPARδ with marked selectivity over PPARα and PPARγ in co-activator and reporter assays. This selectivity underpins its use as a research tool in metabolic and endurance-related pathways.
Cardarine functions as a metabolic modulator by binding to PPARδ nuclear receptors. Once activated, these receptors regulate the transcription of genes involved in lipid catabolism, fatty acid oxidation, glucose uptake, mitochondrial function, and overall energy metabolism. Activation of PPARδ is associated with recruitment of the coactivator PGC-1α, which in turn enhances the expression of proteins linked to energy expenditure and oxidative metabolism. This signaling can intersect with AMPK–PGC-1α regulatory networks in some models, though GW-501516 is not a direct AMPK activator.
In preclinical animal models, Cardarine has been observed to shift skeletal muscle toward greater utilization of fatty acids as an energy substrate, supporting improved oxidative capacity and endurance-related metabolic changes. These mechanistic findings have made GW-501516 a frequent subject of experimental research on metabolic regulation, endurance physiology, and lipid metabolism.
How Cardarine Works
Cardarine, also known as GW-501516, is a synthetic compound that exerts its effects by selectively activating the peroxisome proliferator-activated receptor delta (PPARδ). This receptor plays a pivotal role in regulating the body’s metabolism, particularly in tissues with high energy demands such as skeletal muscle and the heart. When Cardarine binds to PPARδ, it triggers a cascade of gene expression changes that enhance the breakdown and utilization of fatty acids, boost mitochondrial function, and support overall energy balance.
By promoting the β-oxidation of fatty acids, Cardarine helps the body convert fat into usable energy more efficiently, which can lead to improved physical performance and enhanced endurance. This metabolic shift has been associated in preclinical studies with improved endurance performance and more favorable lipid profiles, which are of interest in cardiometabolic research contexts. Unlike selective androgen receptor modulators (SARMs), Cardarine does not interact with androgen receptors or influence hormone levels; instead, it acts as a metabolic modulator, fine-tuning the body’s energy systems at the cellular level. As a result, GW-501516 has become a widely discussed compound in research circles for its potential to support metabolism, energy expenditure, and overall health.
Function of PPAR Agonists
Data indicates that PPAR activity preserves glucose for use in tissues like the brain while promoting the mobilization of fatty acids for muscular endurance. PPAR has also been observed to play an important role in temperature regulation, inflammation mediation, mitochondrial respiration, keratinocyte differentiation, and skin and muscle repair. Molecular analyses revealed that PPAR regulates the expression of genes associated with contractile proteins, lipid oxidation, and mitochondrial biogenesis.
PPAR Effects during Fasting
The effects of PPAR are observed in particular during fasting, when free fatty acids are released into the blood. A study in PPAR-null mice demonstrated that the absence of PPAR results in elevated free fatty acids during fasting, lipid accumulation in the liver and heart, low blood sugar, low body temperature, ketones in urine, and ultimately a premature death. Mice naturally adapt to high free fatty acid levels during fasting through the induction of cardiac and hepatic PPAR genes that improve fatty acid uptake and oxidation.
The benefits and side effects of GW-501516, however, have not been confirmed by the Food and Drug Administration (FDA), and like other SARMs for sale, it should be used for research purposes only. Due to its tendency to increase endurance and energy, the World Anti-Doping Agency (WADA) has banned the use of Cardarine in professional sports, and several athletes have tested positive for Cardarine and were dismissed, as this chemical is only for researchers and clinical trials.
Research Applications
Cardarine (GW-501516) has attracted significant attention in both animal research and early human clinical trials for its potential to address a range of metabolic and cardiovascular conditions. While initial clinical investigations provided limited early data, the vast majority of findings to date come from preclinical and mechanistic studies conducted in animals and in vitro models. These results should not be interpreted as evidence of safety or efficacy in humans, and Cardarine remains an investigational compound that has not been approved for medical use.
Early research explored its potential in the context of obesity, diabetes, dyslipidemia, and cardiovascular disease, examining its ability to reduce body fat, improve insulin sensitivity, and influence metabolic function under controlled experimental conditions. Although clinical development was ultimately halted due to findings of liver toxicity and rapid cancer development in multiple organs in long-term rodent studies, Cardarine remains a widely discussed topic in the scientific community for its role in studying PPARδ activation and metabolic regulation.
In the context of athletic performance research, preclinical exercise models have investigated whether PPARδ activation by GW-501516 may influence energy balance, fat oxidation, and endurance-related pathways. Importantly, these effects have only been observed in controlled experimental systems, and no approved human applications exist. While such findings have informed ongoing research into fat metabolism, body composition, and performance physiology, they should not be interpreted as established human benefits.
It is essential to emphasize that Cardarine is not approved for human consumption, is not a dietary supplement, and must not be used outside of legitimate research environments. Ongoing studies continue to explore its effects on metabolic pathways, body composition, and cardiovascular health within preclinical frameworks, but all use should remain strictly within the boundaries of controlled scientific investigation.
Research Applications (Preclinical Context)
Research on Cardarine has investigated several key areas:
Lipid Metabolism and Energy Balance: Studies in cell and animal models have examined effects on fatty acid transport, oxidation, and mitochondrial activity, including preclinical evidence of changes in fat oxidation and body fat regulation.
Glucose Metabolism and Insulin Resistance: Preclinical data suggest that Cardarine may affect glucose uptake and insulin sensitivity in experimental models. However, this has not been confirmed in long-term human studies.
Endurance and Physical Performance: Animal research has evaluated PPARδ activation in pathways associated with increased endurance and exercise capacity, including mechanisms relevant to skeletal muscle substrate use.
Cardiometabolic Models: Experimental models have explored changes in lipid profiles, inflammatory markers, and vascular health parameters that may be relevant to metabolic and cardiovascular research.
These research applications are preclinical only. Cardarine is not approved as a drug, dietary supplement, or performance enhancer, and it should only be used under controlled laboratory conditions for legitimate research purposes.
Clinical Studies
Early human clinical trials of Cardarine were conducted to explore its potential in treating metabolic and cardiovascular disorders, including obesity and dyslipidemia. Short-term studies showed increases in HDL cholesterol, but development was halted in 2007 after long-term rodent studies revealed multi-organ tumor formation at high exposures. No long-term safety data in humans are available.
Cardarine is not FDA-approved, not a dietary or sports supplement, and banned by the World Anti-Doping Agency (WADA) due to its performance-enhancing potential. Several athletes have tested positive for GW-501516 in doping controls, resulting in sanctions. In many jurisdictions (including Australia), Cardarine is illegal to sell or supply for human use.
Several animal studies have been performed that point to Cardarine’s ability to enhance specific physiological processes related to energy metabolism, as well as potential improvements in blood lipids:
One study on mice found that GW-501516 promotes fatty acid oxidation and fat burning in skeletal muscle tissue and alleviates metabolic syndrome.
Another study found that peroxisome proliferator-activated receptors can significantly enhance running endurance in Kunming mice.
Yet another study on mice revealed that PPARs augment exercise endurance by preventing the exhaustion of glucose (“hitting the wall”).
A study involving obese rhesus monkeys found that GW-501516 increased high-density lipoprotein (HDL) and lowered very-low-density lipoprotein (VLDL), indicating potential cardioprotective effects from Cardarine.
Two separate phase II clinical studies found positive effects of Cardarine on obesity, diabetes, dyslipidemia, and cardiovascular disease, as well as suppression of macrophage-derived inflammation.
A study in rats fed a high-fructose diet found that GW-501516 reduced inflammatory markers, especially in the liver, and increased the expression of genes that regulate beta-oxidation.
Side Effects
While Cardarine is not known to cause androgenic side effects like anabolic androgenic steroids, data in rats indicates that doses of 3 mg/kg/day (180-240 mg per day in the average 60-80 kg adult), significantly higher than those used in mammalian trials, caused cancer to develop quickly in several organs. Anecdotal data online indicates a few noticeable side effects. Still, more research is necessary to determine the overall safety profile of GW-501516 before it can be approved for human use by the FDA.
Intended Use: Laboratory research only; not for human or veterinary use
Storage: Store in a cool, dry place away from direct sunlight to maximize shelf life.
30 mL of liquid Cardarine per bottle, containing 20 milligrams per milliliter.
Includes a graduated 1 mL glass pipette for convenient measurement.
Glass bottle with UV resistance to minimize degradation.
Tamper-proof seal to ensure safety in transit.
Less than 5% variance in concentration, guaranteeing consistency.
Formulated and packaged to prevent evaporation in storage.
SKU: 2
This preparation is for laboratory research purposes only and is not approved by the FDA for human consumption. Cardarine/GW-501516 IS NOT A DIETARY OR SPORTS SUPPLEMENT.
Safety Considerations
The safety profile of Cardarine (GW-501516) is a critical area of concern, largely informed by preclinical animal studies rather than large-scale human clinical data. Long-term rodent research identified liver toxicity and the development of cancers in multiple organs at relatively high doses and extended exposure durations. These findings led to the termination of Cardarine’s clinical development programs and continue to shape the regulatory stance on this compound.
Cardarine has been classified as a prohibited substance by the World Anti-Doping Agency (WADA) due to its potential health risks, performance-enhancing effects, and the absence of sufficient human clinical trials to establish a comprehensive safety profile. Reported adverse effects from limited human exposure and anecdotal reports include stomach pain, headaches, and in more severe cases, organ toxicity. The preclinical toxicology data—particularly findings of rapid tumor development in rodent studies—remain a central reason why Cardarine is not approved for medical or dietary use.
Because Cardarine is not considered safe for human consumption, is not FDA-approved, and is not a dietary supplement, any handling or study of the compound should occur strictly within controlled laboratory research settings. The risks associated with improper or unsupervised use highlight the importance of sourcing only high-purity, third-party tested Cardarine from reputable suppliers. Counterfeit, contaminated, or substandard products circulating through unregulated markets can significantly increase the risk of adverse effects.
It is also important to clarify that no approved human dosing protocols exist, and any discussion of dosage should remain confined to preclinical research contexts. As with any experimental compound, appropriate laboratory safety procedures, institutional oversight, and adherence to all regulatory requirements are essential. Consultation with qualified professionals is strongly advised before initiating any research involving GW-501516 to ensure compliance and minimize potential harm.
Safety Information (Non-Clinical)
Carcinogenicity: High-dose, long-duration rodent studies observed rapid development of tumors in multiple organs (e.g., liver, stomach, thyroid).
Hepatotoxicity: Preclinical and case literature indicate potential liver stress and elevated liver enzymes.
Cardiometabolic Effects: Effects on blood pressure, blood lipids, and heart health remain under investigation.
Unknown Human Safety: There is no approved therapeutic use, and long-term human safety data are lacking.
Cardarine is not known to cause androgenic effects like anabolic steroids, but its unapproved status and preclinical risk profile warrant caution. Excessive intake in experimental settings has been associated with increased health risks, emphasizing the importance of controlled dosing and adherence to research protocols.
Scientific References:
1. T. Tanaka et al., Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome, Proc. Natl. Acad. Sci. U.S.A., vol. 100, no. 26, pp. 15924–15929, Dec. 2003
2. Chen, W. et al. A metabolomic study of the PPARd agonist GW-501516 for enhancing running endurance in Kunming mice. Sci. Rep. 5, 09884; Doi: 10.1038/srep09884 (2015)
3. Fan W., Waizenegger W., Lin C.S., Sorrentino V., He M.-X., Wall C.E., Li H., Liddle C., Yu R.T., Atkins A.R., et al. PPARδ Promotes Running Endurance by Preserving Glucose. Cell Metab. 2017;25:1186–1193.e1184. doi: 10.1016/j.cmet.2017.04.006
4. What is GW-501516 (aka Cardarine)? Sports Technology Labs 2023.
5. Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5306-11. doi: 10.1073/pnas. 091021198. Epub 2001 Apr 17. PMID: 11309497; PMCID: PMC33205.
6. Sprecher DL. Lipids, lipoproteins, and peroxisome proliferator-activated receptor-delta. Am J Cardiol. 2007 Dec 3;100(11 A):n20-4. Doi: 10.1016/j.amjcard.2007.08.009. PMID: 18047848.
7. Barish GD, Narkar VA, Evans RM. PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest. 2006 Mar;116(3):590-7. doi: 10.1172/JCI27955. PMID: 16511591; PMCID: PMC1386117.
8. Dressel U, Allen TL, Pippal JB, Rohde PR, Lau P, Muscat GE. The peroxisome proliferator-activated receptor beta/delta agonist, GW-501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol Endocrinol. 2003 Dec;17(12):2477-93. doi: 10.1210/me. 2003-0151. Epub 2003 Oct 2. PMID: 14525954.
9. Sahebkar A, Chew GT, Watts GF. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin Pharmacother. 2014 Mar;15(4):493-503. doi: 10.1517/14656566.2014.876992. Epub 2014 Jan 16. PMID: 24428677.
10. Teresa Coll, David Álvarez-Guardia, Emma Barroso, Anna Maria Gómez-Foix, Xavier Palomer, Juan C. Laguna, Manuel Vázquez-Carrera, Activation of Peroxisome Proliferator-Activated Receptor-δ by GW-501516 Prevents Fatty Acid-Induced Nuclear Factor-κB Activation and Insulin Resistance in Skeletal Muscle Cells, Endocrinology, Volume 151, Issue 4, 1 April 2010, Pages 1560–1569
11. Magliano, D.C., Penna-de-Carvalho, A., Vazquez-Carrera, M. et al. Short-term administration of GW-501516 improves the inflammatory state in white adipose tissue and liver damage in high-fructose-fed mice through modulation of the renin-angiotensin system. Endocrine 50, 355–367 (2015).
12. Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. JAMA. 2017 Nov 28;318(20):2004-2010. doi: 10.1001/jama.2017.17069. Erratum in: JAMA. 2018 Feb 20;319(7):724. PMID: 29183075; PMCID: PMC5820696.
13. Burri L, Thoresen GH, Berge RK. The Role of PPARα Activation in Liver and Muscle. PPAR Res. 2010;2010:542359. doi: 10.1155/2010/542359. Epub 2010 Aug 18. PMID: 20847941; PMCID: PMC2933910.
14. Leone TC, Weinheimer CJ, Kelly DP. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7473-8. doi: 10.1073/pnas. 96.13.7473. PMID: 10377439; PMCID: PMC22110.
